Intranasal delivery of bryostatin-1 using surface charge-engineered lipid nanoparticles to modulate mucosal defense for allergic rhinitis treatment.

In addition, although we observed a clear trend in IgA induction increase after the administration of bryo-1@A-LNPs-40, the lack of statistically significant differences in IgE suppression among the LNP formulations indicates that the current platform may primarily function as a potent mucosal immune modulator rather than an immediate suppressor of established allergic cascades.

also in 19,460 other papers

N-LNPs showed a trend toward clearance into oral cavity via nose-throat path (strong oral cavity fluorescence) and exhibited lower overall fluorescence intensity than the other two formulations, indicating more rapid transit through the nasal cavity.

also in 53,322 other papers